Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Tegoprazan in Healthy Males
NCT03530228Phase 1Unknown
- Sponsor
- HK inno.N Corporation
- Start
- May 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) and Peptic ulcer disease (PUD) (7 arms), sponsored by HK inno.N Corporation. Primary endpoints: Area Under the Curve (AUC0-24h) up to 7 days, Maximum Plasma Concentration (Cmax) up to 7 days and 2 more. Status: unknown.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)Peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT03530228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03530228.